What does IMMUCELL CORP /DE/ (ICCC) do?

IMMUCELL CORP /DE/ (ICCC) is a publicly traded company in the Healthcare sector.

What sector does ICCC operate in?

IMMUCELL CORP /DE/ operates in the Healthcare, specifically within the In Vitro & In Vivo Diagnostic Substances industry. AlphaOS tracks cycle stage, supply-chain relationships, and investment intelligence for companies across all sectors.

Where can I find ICCC earnings analysis?

AlphaOS publishes an earnings intelligence page for IMMUCELL CORP /DE/ (ICCC) covering results, guidance context, and AI-assisted analysis. See /stocks/ICCC/earnings. Content is for research and education — not investment advice.

Intelligence coverage: 60%

Basic profile, financials, and market data are shown below. Deep research is building in the background.

ICCC

IMMUCELL CORP /DE/

Healthcare · In Vitro & In Vivo Diagnostic Substances

$9.88Sep 28, 2026

AI confidence 71% · prior close shown (market closed)

Investment Snapshot

Weak evidence · 1 source

Why it matters

IMMUCELL CORP /DE/ shows decelerating business momentum based on AlphaOS pipeline evidence.

Why it matters: Revenue +12% YoY in Q2 FY2026.

TrajectoryDecelerating

3 signals not yet derived from pipeline evidence

Key signals

What it means for the thesis — synthesis, not a raw event feed.

Revenue +12% YoY in Q2 FY2026

Pipeline evidence · 0d ago

ICCC's AlphaOS Signals

Upgrade to Pro for validated historical pattern analysis on ICCC.

Create free account

Free accounts see more of this; Premium sees all of it.

Latest earnings · Q2 2026

Full ICCC earnings analysis

Reported figures for IMMUCELL CORP /DE/ — research only, not investment advice.

Revenue YoY: +11.6%
EPS YoY: +233.3%

Latest Intelligence

Updated September 29, 2026

What happened recently for IMMUCELL CORP /DE/ (ICCC) — events, not interpretation.

Event: Reported Q2 2026 revenue +12% YoY.
Also: Last session September 28, 2026 at $9.88.
Source: Q2 2026 earnings

Research & analysis only — not investment advice.

Building company intelligence…

IMMUCELL CORP /DE/ (ICCC)

Healthcare · In Vitro & In Vivo Diagnostic Substances

Investment Snapshot above is the primary AlphaOS analysis for IMMUCELL CORP /DE/ — structured signals and evidence from proprietary pipelines, not an encyclopedia overview.

Key facts

Sector:: Healthcare
Industry:: In Vitro & In Vivo Diagnostic Substances
Market cap:: $89.73M
Revenue:: $7.19M

ICCC earnings analysis

Research & analysis only — not investment advice. Price, charts, and filings are above.

Connected intelligence

Follow IMMUCELL CORP /DE/ through AlphaOS's knowledge graph — themes, peers, beneficiaries, earnings, and research answers.

Connected companies and research pages from the AlphaOS knowledge graph.